In the United States, Rotavirus Gastroenteritis (RGE) has significant consequences for infants and young children [4]
- Up to 272,000 ED visits and 70,000 hospitalizations annually [4]
- No reliable way to know which infants will have severe disease [4]
RGE is an important cause of hospitalizations [6]
- More than 70% of pediatric hospitalizations for GE are due to rotavirus during peak season [4]
- Children hospitalized for RGE experience significantly longer hospitals stays than those hospitalized for other causes of GE [7]
Hospitalizations for RGE in Children ≤ 5 Years of Age in the US* [7]
*Study conducted in New York State, 1993–2000 data.
NEXT: Symptoms & Severity>>Indications and Usage
ROTARIX is indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series in infants and children.
Important Safety Information
- In clinical studies, common adverse events were fussiness/irritability, cough/runny nose, fever, loss of appetite, and vomiting.
- History of uncorrected congenital malformation of the gastrointestinal tract is a contraindication.
- Previous hypersensitivity to any component of ROTARIX, including latex rubber, should be reviewed prior to administration.
- Administration in infants suffering from acute diarrhea or vomiting should be delayed.
- Safety and effectiveness in infants with chronic gastrointestinal disorders, or with known primary or secondary immunodeficiencies, have not been evaluated.
 |
Download Complete Prescribing Information for ROTARIX |
